A Phase 1 interventional study of CVX-045 in Advanced Solid Tumors, Neoplasms and Carcinoma, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-13.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
9,359 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.
This study's enrollment of 40 is below the median of 50 across 7,250 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 581 completed or terminated interventional studies of FDA-regulated products, 380 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: CVX-045
Weekly, intravenous dose
To determine safety and tolerability of CVX-045 as weekly intravenous (IV) infusions in adult patients with advanced solid tumors
Time frame: Throughout duration of study
To identify and characterize CVX-045-related adverse events (AEs)
Time frame: Throughout duration of study
To evaluate the plasma pharmacokinetics (PK) of CVX-045
Time frame: Days 1, 4, 8, 15, 29
To determine a recommended Phase 2 dose of CVX-045
Time frame: End of study
To evaluate the potential for immunogenicity of CVX-045
Time frame: Days 1, 15, 1st day of every subsequent cycle, EOS, 30 Day FU
To document any preliminary evidence of antitumor activity
Time frame: Every 8 weeks
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer